Last updated: February 19, 2026
This report provides a detailed analysis of Russian Federation drug patent RU2581045, focusing on its scope, claims, and the surrounding patent landscape. The patent, titled "Means for treatment of prostate hyperplasia and prostatitis," was granted to Novosibirskaia Gosudarstvennaia Meditsinskaia Akademiia (Novosibirsk State Medical Academy) on April 10, 2016 [1].
What is the Core Invention of RU2581045?
The patent RU2581045 describes a pharmaceutical composition intended for treating benign prostatic hyperplasia (BPH) and prostatitis. The composition is based on a combination of active ingredients.
What are the Claimed Active Ingredients?
The claimed active ingredients are:
- A standardized extract of the fruit of Tribulus terrestris L. (caltrop).
- A standardized extract of the root of Rhodiola rosea L. (golden root).
- Zinc oxide.
The patent specifies that these components are present in precise proportions within the pharmaceutical composition [1].
What is the Intended Mechanism of Action?
The patent suggests that the combination of these ingredients provides a synergistic effect, contributing to the treatment of prostate conditions. Tribulus terrestris is traditionally used for its effects on hormone balance and urological health. Rhodiola rosea is an adaptogen known for its anti-inflammatory and antioxidant properties. Zinc oxide is included, and zinc plays a crucial role in prostate health and immune function [1]. The specific synergistic mechanism is not detailed beyond the combined therapeutic effect.
What is the Scope of the Patent's Claims?
The claims of RU2581045 define the legal boundaries of the invention. The primary claim focuses on the pharmaceutical composition itself.
What is Claim 1 of RU2581045?
Claim 1 of RU2581045 reads as follows: "Pharmaceutical composition for treatment of hyperplasia of prostate and prostatitis, comprising: a standardized extract of the fruit of Tribulus terrestris L., a standardized extract of the root of Rhodiola rosea L., and zinc oxide [1]." This claim is broad, covering any pharmaceutical composition containing these three components for the specified indications.
Are There Dependent Claims?
While the publicly available abstract for RU2581045 does not detail all dependent claims, patent structures typically include dependent claims that narrow the scope of the independent claims. These might specify particular concentrations of the active ingredients, specific extraction methods, or dosage forms (e.g., tablets, capsules) [1]. A full review of the patent’s detailed claims document would be required for complete understanding.
What is the Patent Landscape for Prostate Health Pharmaceuticals in Russia?
The patent landscape for prostate health treatments in Russia is diverse, encompassing both synthetic drugs and natural product-based formulations. Patents in this area often focus on novel compounds, new formulations of existing drugs, or specific therapeutic uses.
What Other Patents Exist for Tribulus terrestris in Russia?
Patents related to Tribulus terrestris in Russia may cover its use in various conditions, not exclusively prostate health. Older patents might exist for general herbal preparations or specific extraction techniques. For example, patents may cover compositions for treating erectile dysfunction or improving male reproductive health, where Tribulus terrestris is a common ingredient. A comprehensive search of the Russian Federal Service for Intellectual Property (Rospatent) database would reveal specific patents.
What Other Patents Exist for Rhodiola rosea in Russia?
Similarly, Rhodiola rosea is patented for a range of applications. These can include adaptogenic properties, treatment of fatigue, neurological disorders, and immune system support. Specific formulations for treating inflammatory conditions, including those affecting the prostate, could also be patented.
What is the Patent Situation for Zinc-Based Prostate Treatments?
Zinc compounds, particularly zinc oxide and zinc citrate, have been investigated and patented for their role in BPH and prostatitis management. Patents in this area might focus on specific dosages, delivery systems (e.g., sustained-release formulations), or combinations with other active agents to enhance efficacy or reduce side effects.
How Does RU2581045 Compare to Other Prostate Health Patents?
RU2581045 stands out by combining three distinct natural and mineral components into a single pharmaceutical composition specifically for BPH and prostatitis. Many other patents might focus on single-ingredient natural products, synthetic pharmaceuticals, or different combinations. The patent's strength lies in its claim to a specific formulation. However, its novelty and inventiveness would be evaluated against prior art, which includes any published information or existing patents describing similar combinations or uses. The broad nature of Claim 1 suggests a focus on the combination itself as the primary innovation.
Are There Any Potential Patent Infringement Concerns?
Companies developing or marketing pharmaceutical compositions for BPH and prostatitis in Russia must conduct thorough freedom-to-operate analyses. If a competitor's product contains the standardized extract of Tribulus terrestris fruit, a standardized extract of Rhodiola rosea root, and zinc oxide, and is marketed for treating prostate hyperplasia or prostatitis, it could potentially infringe upon Claim 1 of RU2581045, depending on the specific formulation and claims of the competitor's product [1]. The definition of "standardized extract" can also be a point of contention in infringement cases, as it implies a consistent level of active compounds.
What is the Competitive Landscape for BPH and Prostatitis Treatments in Russia?
The market for BPH and prostatitis treatments in Russia includes a wide array of therapeutic options. These range from prescription medications (alpha-blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors) to over-the-counter remedies and herbal supplements.
What are the Primary Market Segments?
- Pharmaceuticals: This segment includes drugs prescribed by physicians for managing symptoms and underlying causes of BPH and prostatitis.
- Dietary Supplements/Herbal Remedies: This segment is significant in Russia and often includes products based on natural ingredients like saw palmetto, pygeum, Tribulus terrestris, and Rhodiola rosea. RU2581045 falls within this segment, though patented formulations aim for a higher level of standardization and therapeutic claims than typical supplements.
- Medical Devices: Devices for surgical or minimally invasive treatments are also part of the broader landscape.
How Do Patented Natural Formulations Compete?
Patented natural formulations like the one described in RU2581045 aim to differentiate themselves from generic herbal products by offering:
- Standardization: Ensuring consistent potency and efficacy, which is often a weakness of unregulated supplements.
- Specific Therapeutic Claims: Backed by patent protection, allowing for targeted marketing for BPH and prostatitis.
- Potential for Clinical Support: Patents often stem from research that may lead to clinical trials, providing further evidence of efficacy.
What is the role of Traditional Medicine in Russia?
Traditional and phytotherapy (herbal medicine) play a substantial role in healthcare in Russia. Many consumers actively seek natural remedies due to perceived safety and cultural preference. This creates a receptive market for well-formulated and scientifically presented herbal products, especially those with patent protection that lends them an air of validation.
Key Takeaways
RU2581045 claims a pharmaceutical composition for treating prostate hyperplasia and prostatitis, based on a combination of standardized extracts of Tribulus terrestris and Rhodiola rosea, along with zinc oxide. The patent's broad claim scope covers any composition containing these three ingredients for the specified indications. The Russian patent landscape for prostate health is populated with diverse treatments, including pharmaceuticals and natural remedies. Companies operating in this space must navigate existing patents and conduct freedom-to-operate assessments, as products containing the patented combination could be subject to infringement claims. The growing consumer interest in natural health solutions in Russia supports the market potential for such patented formulations, provided they can demonstrate consistent efficacy and safety.
Frequently Asked Questions
- Does RU2581045 claim a specific extraction process for Tribulus terrestris or Rhodiola rosea?
The patent abstract primarily claims the composition. Dependent claims, not fully detailed in the abstract, might specify extraction methods, but the independent claim focuses on the presence of standardized extracts.
- What constitutes a "standardized extract" as per RU2581045?
The patent document itself would define the required standardization parameters. This typically involves specifying the minimum percentage of key active compounds (e.g., saponins for Tribulus terrestris, rosavins for Rhodiola rosea) within the extract.
- Can companies sell Tribulus terrestris, Rhodiola rosea, and zinc oxide separately as supplements without infringing RU2581045?
Yes, selling these ingredients as individual dietary supplements for general wellness would likely not infringe. Infringement occurs when a composition containing all three is marketed for the patented indications.
- What is the expiration date for RU2581045?
As a Russian Federation patent, its term is typically 20 years from the filing date, subject to any applicable extensions or maintenance requirements. The filing date would need to be confirmed from the official patent record.
- Has RU2581045 been licensed or is it actively being marketed by the patent holder?
Information regarding licensing agreements or active commercialization by Novosibirsk State Medical Academy is not available in the patent abstract. Further due diligence would be required to ascertain its commercial status.
Citations
[1] Novosibirskaia Gosudarstvennaia Meditsinskaia Akademiia. (2016). Patent RU2581045 C1: Means for treatment of prostate hyperplasia and prostatitis. Federal Service for Intellectual Property (Rospatent).
